Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

NCT06796114 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Centre Hospitalier Universitaire de Besancon

Collaborators